Pulmonary arterial hypertension, or PAH, can make everyday activities difficult. But a new treatment may be on the horizon. Only days after selexipag got approval from the US FDA, a new study was published showing the drug’s potential for treating PAH. This study found that selexipag successfully cut the rates of hospitalization and worsening symptoms among PAH patients by 40 percent compared to placebo. PAH is a condition marked by abnormally high blood pressure in the blood vessel that carries blood from the heart to the lungs. Selexipag works to target a known disease pathway that opens blood vessels to the lungs and improves heart function. This treatment is easier to use than other PAH treatments delivered by infusion or injection. Ask your doctor about newly approved medications
Content
3.48 -> I'm Shelby Cullinan with today's health news.
6.22 -> Pulmonary arterial hypertension, or PAH, can
make everyday activities difficult.
12.23 -> But a new treatment may be on the horizon.
15.07 -> Only days after selexipag got approval from
the US FDA, a new study was published showing
20.86 -> the drug's potential for treating PAH.
23.779 -> This study found that selexipag successfully
cut the rates of hospitalization and worsening
29.3 -> symptoms among PAH patients by 40 percent
compared to placebo.
34.32 -> PAH is a condition marked by abnormally high
blood pressure in the blood vessel that carries
39.51 -> blood from the heart to the lungs.
42.35 -> Selexipag works to target a known disease
pathway that opens blood vessels to the lungs
47.62 -> and improves heart function.
49.71 -> This treatment is easier to use than other
PAH treatments delivered by infusion or injection.
56.04 -> Ask your doctor about newly approved medications.
